




LCKLSL acetate

Cat. No.: RC35029
CAS No.: 533902-29-3
分子式: C30H57N7O8S
分子量: 675.88
Sequence: Leu-Cys-Lys-Leu-Ser-Leu
作用靶点: Others
作用通路: Others
储存方式: keep away from moisture
 Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Description LCKLSL, an N-terminal hexapeptide, acts as a competitive inhibitor of annexin A2 (AnxA2), effectively preventing the binding of tissue plasminogen activator (tPA) to AnxA2 while also inhibiting the generation of plasmin. In addition, LCKLSL exhibits anti-angiogenic properties.

In vitro In human retinal microvascular endothelial cells (RMVECs), administering LCKLSL at doses ranging from 0 to 2 mg reduces plasmin production and diminishes the activity of tissue plasminogen activator (tPA) stimulated by vascular endothelial growth factor (VEGF) under conditions of low oxygen (hypoxia).

In vivo Utilizing LCKLSL in two in vivo models (in chicken chorioallantoic membrane and murine Matrigel plug assays) for studying angiogenesis has shown to inhibit angiogenic responses. Administering the LCKLSL peptide considerably reduces vascular length. Furthermore, at a concentration of 5 µg/mL, it markedly diminishes vascular branch, junction, and end-point counts.

Solutions	1mg	5mg	10mg
1 mM	1.4795 mL	7.3977 mL	14.7953 mL
5 mM	0.2959 mL	1.4795 mL	2.9591 mL
10 mM	0.148 mL	0.7398 mL	1.4795 mL
50 mM	0.0296 mL	0.148 mL	0.2959 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.